Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on GS 101. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113429439A details a high-yield synthesis of GS-101, a key tenofovir prodrug intermediate, offering significant cost reduction in API manufacturing through optimized catalytic conditions.